The authors report on an echocardiographic sub-study of the NOTION trial, a prospective randomized study which compared outcomes between 120 patients undergoing TAVI and 112 patients undergoing aortic valve replacement (AVR).
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
TAVR (TAVI)
December 27, 2016
The authors report on their findings an ongoing Japanese multicentre prospective registry. They evaluate outcomes in 478 patients undergoing transfemoral TAVI and treated with percutaneous puncture using an expandable sheath, Edwards Sapien XTprosthesis and a Perclose ProGlide system.
November 23, 2016
Valve in valve transcatheter aortic valve implantation (ViV-TAVI) is an alternative to redo surgical aortic valve replacement (SAVR) in inoperable patients and inpatients at high operative risk.
October 31, 2016
This single institution retrospective study evaluated outcomes of valve replacement for degenerated bioprosthetic aortic valves comparing surgical AVR (SAVR) to transcatheter valve-in-valve procedures (TViV). Patients were matched into 2 groups of 22 according to STS risk scores. Operative mortality, stroke rate, and 3-year survival were similar b
October 13, 2016
This is the first report of the use of a balloon expandable transcatheter heart valve (Edwards Sapiens 3) for TAVI in chronic aortic regurgitation (AR) involving non-calcified native valves. The authors implanted Edwards Sapiens 3 prostheses in three patients with severe AR deemed inoperable by the heart team.
September 27, 2016
This analysis of PARTNER data evaluated the impact of chronic kidney disease (CKD) on outcomes after TAVR. Patients were grouped according to GFR as none/mild, moderate, and severe renal disease. Severe disease was most common among women with diabetes.
September 12, 2016
The presence of a bicuspid valve has been considered as a relative contraindication for transcatheter aortic valve implantation (TAVI). This a multicentre retrospective study of 51 patients with bicuspid aortic stenosis who had undergone TAVI using a next-generation transcatheter heart valve (Edwards SAPIEN 3). 30- day mortality was 3,9%.
September 7, 2016
This multistudy registry, entitled ROUTE, studied the effectiveness and safety of transaortic access for TAVI in 301 patients. Mean age was 82 years and mean STS Score 9.0. Valve success was 97%.
September 6, 2016
In this retrospective review of 460 consecutive patients undergoing transcatheter aortic valve implantation with the Edwards Sapiens XT or Sapiens 3 prosthesis, the authors analyse the incidence, clinical implications and predisposing factors related to trancatheter heart valve (THV) thrombosis.
August 9, 2016
In this study the investigators aimed to study whether a cerebral protection device during TAVI reduced the number of cerebral lesions in patients undergoing TAVI.